Compare GO & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GO | ACRS |
|---|---|---|
| Founded | 1946 | 2012 |
| Country | United States | United States |
| Employees | 2207 | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 748.6M |
| IPO Year | 2019 | 2015 |
| Metric | GO | ACRS |
|---|---|---|
| Price | $9.01 | $5.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $11.30 | $10.20 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,759,000.00 | $1,683,000.00 |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $3.91 | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $5.66 | $1.46 |
| 52 Week High | $19.41 | $5.88 |
| Indicator | GO | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.33 | 49.39 |
| Support Level | $9.01 | $4.13 |
| Resistance Level | $10.54 | $5.85 |
| Average True Range (ATR) | 0.37 | 0.31 |
| MACD | -0.16 | -0.05 |
| Stochastic Oscillator | 13.54 | 2.34 |
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.